Search Results - "Geary, Richard S"

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides by Geary, Richard S., Norris, Daniel, Yu, Rosie, Bennett, C. Frank

“…Pharmacokinetic properties of oligonucleotides are largely driven by chemistry of the backbone and thus are sequence independent within a chemical class…”
Get full text

Pharmacology of Antisense Drugs by Bennett, C. Frank, Baker, Brenda F, Pham, Nguyen, Swayze, Eric, Geary, Richard S

“…Recent studies have led to a greater appreciation of the diverse roles RNAs play in maintaining normal cellular function and how they contribute to disease…”
Get full text

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels by Alexander, Veronica J, Xia, Shuting, Hurh, Eunju, Hughes, Steven G, O’Dea, Louis, Geary, Richard S, Witztum, Joseph L, Tsimikas, Sotirios

“…Abstract Aims Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease. AKCEA-APOCIII-LRx is an…”
Get full text

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B by Geary, Richard S., Baker, Brenda F., Crooke, Stanley T.

“…Mipomersen (Kynamro ® ), a second-generation 2′- O -methoxyethyl chimeric antisense oligonucleotide (ASO), inhibits the synthesis of apolipoprotein B (apoB)…”
Get full text

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B by Crooke, Stanley T., Geary, Richard S.

“…Mipomersen is a second generation antisense oligonucleotide that targets apolipoprotein B. It has been studied thoroughly in clinical trials (more than 800…”
Get full text

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides by Graham, Mark J, Lee, Richard G, Brandt, Teresa A, Tai, Li-Jung, Fu, Wuxia, Peralta, Raechel, Yu, Rosie, Hurh, Eunju, Paz, Erika, McEvoy, Bradley W, Baker, Brenda F, Pham, Nguyen C, Digenio, Andres, Hughes, Steven G, Geary, Richard S, Witztum, Joseph L, Crooke, Rosanne M, Tsimikas, Sotirios

“…Angiopoietin-like 3 (ANGPTL3) inhibits endothelial lipase and lipoprotein lipase. Injection of antisense oligonucleotides targeting ANGPTL3 messenger RNA…”
Get full text

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials by Viney, Nicholas J, BSc, van Capelleveen, Julian C, MD, Geary, Richard S, PhD, Xia, Shuting, MS, Tami, Joseph A, PharmD, Yu, Rosie Z, PhD, Marcovina, Santica M, Prof, Hughes, Steven G, MD, Graham, Mark J, MS, Crooke, Rosanne M, PhD, Crooke, Stanley T, MD, Witztum, Joseph L, Prof, Stroes, Erik S, Prof, Tsimikas, Sotirios, Prof

“…Summary Background Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific…”
Get full text

Targeting APOC3 in the Familial Chylomicronemia Syndrome by Gaudet, Daniel, Brisson, Diane, Tremblay, Karine, Alexander, Veronica J, Singleton, Walter, Hughes, Steven G, Geary, Richard S, Baker, Brenda F, Graham, Mark J, Crooke, Rosanne M, Witztum, Joseph L

“…In this study, investigators found that APOC3, a key regulator of triglyceride metabolism, had a profound and clinically relevant effect on triglyceride levels…”
Get full text

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study by Tsimikas, Sotirios, Prof, Viney, Nicholas J, BSc, Hughes, Steven G, MBBS, Singleton, Walter, MD, Graham, Mark J, MS, Baker, Brenda F, PhD, Burkey, Jennifer L, PhD, Yang, Qingqing, MS, Marcovina, Santica M, Prof, Geary, Richard S, PhD, Crooke, Rosanne M, PhD, Witztum, Joseph L, Prof

“…Summary Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic valve stenosis. No effective therapies to lower…”
Get full text

An oral antisense oligonucleotide for PCSK9 inhibition by Gennemark, Peter, Walter, Katrin, Clemmensen, Niclas, Rekić, Dinko, Nilsson, Catarina A M, Knöchel, Jane, Hölttä, Mikko, Wernevik, Linda, Rosengren, Birgitta, Kakol-Palm, Dorota, Wang, Yanfeng, Yu, Rosie Z, Geary, Richard S, Riney, Stan J, Monia, Brett P, Isaksson, Rikard, Jansson-Löfmark, Rasmus, Rocha, Cristina S J, Lindén, Daniel, Hurt-Camejo, Eva, Crooke, Rosanne, Tillman, Lloyd, Rydén-Bergsten, Tina, Carlsson, Björn, Andersson, Ulf, Elebring, Marie, Tivesten, Anna, Davies, Nigel

“…Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol and are used for treatment of…”
Get more information

Clinical pharmacokinetics of second generation antisense oligonucleotides by Yu, Rosie Z, Grundy, John S, Geary, Richard S

“…Multiple "second generation" gapmer antisense oligonucleotides (ASOs) of varying chemistries have been evaluated as potential therapeutic agents in the clinic…”
Get more information

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers by Crooke, Stanley T, Baker, Brenda F, Kwoh, T Jesse, Cheng, Wei, Schulz, Dan J, Xia, Shuting, Salgado, Nelson, Bui, Huynh-Hoa, Hart, Christopher E, Burel, Sebastien A, Younis, Husam S, Geary, Richard S, Henry, Scott P, Bhanot, Sanjay

“…The common chemical and biological properties of antisense oligonucleotides provide the opportunity to identify and characterize chemical class effects across…”
Get full text

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD by Walsh, Michael, Bethune, Claudette, Smyth, Andrew, Tyrwhitt, Jessica, Jung, Shiangtung W., Yu, Rosie Z., Wang, Yanfeng, Geary, Richard S., Weitz, Jeffrey, Bhanot, Sanjay

“…Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of…”
Get full text

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data by Viney, Nicholas J., Guo, Shuling, Tai, Li‐Jung, Baker, Brenda F., Aghajan, Mariam, Jung, Shiangtung W., Yu, Rosie Z., Booten, Sheri, Murray, Heather, Machemer, Todd, Burel, Sebastien, Murray, Sue, Buchele, Gustavo, Tsimikas, Sotirios, Schneider, Eugene, Geary, Richard S., Benson, Merrill D., Monia, Brett P.

“…Aims Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and/or polyneuropathy. AKCEA‐TTR‐LRx…”
Get full text

Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 by YU, Rosie Z, KIM, Tae-Won, AN HONG, WATANABE, Tanya A, GAUS, Hans J, GEARY, Richard S

“…The pharmacokinetics of a 2′- O -(2-methoxyethyl)-modified oligonucleotide, ISIS 301012 [targeting human apolipoprotein B-100 (apoB-100)], was characterized…”
Get full text

Oral delivery of antisense oligonucleotides in man by Tillman, Lloyd G, Geary, Richard S, Hardee, Gregory E

“…Treatment of systemic disease with phosphorothioate antisense oligonucleotides (PS ASOs) has been accomplished using local or parenteral routes of…”
Get more information

Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice by Yu, Rosie Z, Graham, Mark J, Post, Noah, Riney, Stan, Zanardi, Thomas, Hall, Shannon, Burkey, Jennifer, Shemesh, Colby S, Prakash, Thazha P, Seth, Punit P, Swayze, Eric E, Geary, Richard S, Wang, Yanfeng, Henry, Scott

“…Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency via receptor-mediated uptake. In the…”
Get full text

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy by Coelho, Teresa, Ando, Yukio, Benson, Merrill D., Berk, John L., Waddington-Cruz, Márcia, Dyck, Peter J., Gillmore, Julian D., Khella, Sami L., Litchy, William J., Obici, Laura, Monteiro, Cecilia, Tai, Li-Jung, Viney, Nicholas J., Buchele, Gustavo, Brambatti, Michela, Jung, Shiangtung W., St. L. O’Dea, Louis, Tsimikas, Sotirios, Schneider, Eugene, Geary, Richard S., Monia, Brett P., Gertz, Morie

“…Introduction AKCEA-TTR-L Rx is a ligand-conjugated antisense (LICA) drug in development for the treatment of hereditary transthyretin amyloidosis (hATTR), a…”
Get full text

Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN by Geary, Richard S., Wancewicz, Ed, Matson, John, Pearce, Megan, Siwkowski, Andrew, Swayze, Eric, Bennett, Frank

“…Rate and route of administration, and ultimate plasma concentration, alter the effective uptake of antisense oligonucleotide in mouse liver. The role of dose…”
Get full text

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100 by Yu, Rosie Z., Lemonidis, Kristina M., Graham, Mark J., Matson, John E., Crooke, Rosanne M., Tribble, Diane L., Wedel, Mark K., Levin, Arthur A., Geary, Richard S.

“…Similar exposure-response relationships of ISIS 301012 in human ApoB transgenic mice and in humans. ▪ The in vivo pharmacokinetics/pharmacodynamics of 2′-…”
Get full text